DK1372682T3 - Catechiner til behandling af fibrillogenese ved alzheimers sygdom, parkinsons sygdom, systemisk AA amyloidose og andre amyloide forstyrrelser - Google Patents

Catechiner til behandling af fibrillogenese ved alzheimers sygdom, parkinsons sygdom, systemisk AA amyloidose og andre amyloide forstyrrelser

Info

Publication number
DK1372682T3
DK1372682T3 DK02721413.9T DK02721413T DK1372682T3 DK 1372682 T3 DK1372682 T3 DK 1372682T3 DK 02721413 T DK02721413 T DK 02721413T DK 1372682 T3 DK1372682 T3 DK 1372682T3
Authority
DK
Denmark
Prior art keywords
disease
fibrillogenesis
catechins
amyloidosis
parkinson
Prior art date
Application number
DK02721413.9T
Other languages
English (en)
Inventor
Gerardo M Castillo
Paula Y Choi
Joel A Cummings
Beth P Nguyen
Alan D Snow
Original Assignee
Proteotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteotech Inc filed Critical Proteotech Inc
Application granted granted Critical
Publication of DK1372682T3 publication Critical patent/DK1372682T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
DK02721413.9T 2001-03-15 2002-03-15 Catechiner til behandling af fibrillogenese ved alzheimers sygdom, parkinsons sygdom, systemisk AA amyloidose og andre amyloide forstyrrelser DK1372682T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27686601P 2001-03-15 2001-03-15
US33896901P 2001-12-10 2001-12-10
PCT/US2002/007755 WO2003013442A2 (en) 2001-03-15 2002-03-15 Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders

Publications (1)

Publication Number Publication Date
DK1372682T3 true DK1372682T3 (da) 2012-08-20

Family

ID=26958170

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02721413.9T DK1372682T3 (da) 2001-03-15 2002-03-15 Catechiner til behandling af fibrillogenese ved alzheimers sygdom, parkinsons sygdom, systemisk AA amyloidose og andre amyloide forstyrrelser

Country Status (9)

Country Link
EP (1) EP1372682B1 (da)
JP (1) JP2004537576A (da)
AT (1) ATE555807T1 (da)
CA (1) CA2440293C (da)
DK (1) DK1372682T3 (da)
ES (1) ES2387910T3 (da)
NZ (1) NZ528321A (da)
PT (1) PT1372682E (da)
WO (1) WO2003013442A2 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514107B2 (en) * 2002-03-21 2009-04-07 Mars, Incorporated Treatment of diseases involving defective gap junctional communication
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
WO2004060791A1 (en) 2003-01-07 2004-07-22 Ramot At Tel Aviv University Ltd. Peptide nanostructures encapsulating a foreign material and method of manufacturing same
WO2005027901A1 (en) * 2003-09-25 2005-03-31 Tel Aviv University Future Technology Development L.P. Compositions and methods using same for treating amyloid-associated diseases
EP1713457A2 (de) * 2004-02-11 2006-10-25 Max-Delbrück-Centrum Für Molekulare Medizin Neue arzneimittel und diagnostische zusammensetzungen f r be handlung und diagnose von neurodegenerativen erkrankungen und amyloid-krankheiten
WO2006013552A2 (en) 2004-08-02 2006-02-09 Ramot At Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
WO2006116535A1 (en) * 2005-04-26 2006-11-02 University Of South Florida Green tea polyphenol alpha secretase enhancers and methods of use
JP2007022946A (ja) * 2005-07-14 2007-02-01 Mitsui Norin Co Ltd マクロファージ遊走阻止因子の酵素活性阻害剤
WO2007043048A2 (en) 2005-10-11 2007-04-19 Ramot At Tel Aviv University Ltd. Self-assembled fmoc-ff hydrogels
WO2009003147A1 (en) * 2007-06-26 2008-12-31 Parkinson's Institute Methods and compositions for the treatment of neurological disorders
EP2291191A4 (en) * 2008-05-09 2014-01-22 Sinai School Medicine METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES
PT2770988T (pt) 2011-10-24 2016-09-05 Som Innovation Biotech S L Nova terapêutica para a amiloidose associada à transtirretina
EP3305311A4 (en) * 2015-05-27 2019-01-02 Nippon Paper Industries Co., Ltd. Brain function-protecting agent
KR102441381B1 (ko) * 2016-07-18 2022-09-07 (주)아모레퍼시픽 3-O-갈로일-3,3',5,5',7-펜타하이드록시플라반(3-O-galloyl-3,3',5,5',7- pentahydroxyflavan)을 포함하는 인지 기능 개선용 조성물
WO2019054461A1 (ja) * 2017-09-15 2019-03-21 株式会社明治 神経機能の維持または回復用組成物
CN109799352B (zh) * 2019-01-29 2022-03-08 北京健坤禾润科技有限公司 化学发光试剂及其在免疫检测中应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1275905B1 (it) * 1995-03-14 1997-10-24 Indena Spa Frazioni polifenoliche di te', loro uso e formulazioni che le contengono
JPH10245342A (ja) * 1997-03-03 1998-09-14 Mitsui Norin Kk β−アミロイド蛋白の神経細胞毒性低減剤
AU7580098A (en) * 1997-05-15 1998-12-08 University Of Washington Composition and methods for treating alzheimer's disease and other amyloidoses
JP2003519192A (ja) * 1999-12-30 2003-06-17 プロテオテック・インコーポレーテッド アルツハイマー病におけるアミロイド症および他のアミロイド症の治療のためのカテキンおよび緑茶抽出物
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases

Also Published As

Publication number Publication date
JP2004537576A (ja) 2004-12-16
WO2003013442A3 (en) 2003-05-30
ES2387910T3 (es) 2012-10-03
EP1372682A4 (en) 2005-10-19
NZ528321A (en) 2006-09-29
CA2440293C (en) 2012-01-24
EP1372682A2 (en) 2004-01-02
PT1372682E (pt) 2012-08-03
ATE555807T1 (de) 2012-05-15
EP1372682B1 (en) 2012-05-02
CA2440293A1 (en) 2003-02-20
WO2003013442A2 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
DK1372682T3 (da) Catechiner til behandling af fibrillogenese ved alzheimers sygdom, parkinsons sygdom, systemisk AA amyloidose og andre amyloide forstyrrelser
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
NO20100264L (no) Forhindring og behandling av amyloidogen sykdom
DK1014996T3 (da) Præparater indeholdende saccharid til behandling af Alzheimers sygdom og andre amyloidoser
EA200700232A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
ATE330585T2 (de) Behandlung von atemerkrankungen
BRPI0011867B8 (pt) preparação farmacêutica de levodopa/carbidopa/entacapona e processo para preparação da mesma
NO20093464L (no) Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika
IL189546A0 (en) Therapy for the treatment of disease
NO20071267L (no) Forhindring og behandling av synukleinopatiske og amyloidogene sykdommer
CA2426703A1 (en) Therapeutic agents and methods of use thereof for the modulation of angiogenesis
NO20032111L (no) Nye medikamentblandinger basert pa tiotropium-salter og pa salmeterol-salter
NO990595D0 (no) Anvendelse av chelateringsmiddelet clikinol ved fremstilling av en farmas°ytisk sammensetning for behandling av alzheimers sykdom
BR0112674A (pt) Inibidores n-[5-[[[5-alquil-2-oxazolil]metil] tio]-2tiazolil]carboxamida de quinases dependentes de ciclina
ATE529417T1 (de) 3',4',5-trimethoxyflavonderivate als die schleimsekretion stimulierendes mittel, entsprechendes verfahren und pharmazeutische zusammensetzung, die diese enthält
WO2001053457A3 (en) Vaccines against neurodegenerative disorders
WO2002076381A3 (en) Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
ATE427107T1 (de) Eine neue verwendung von deferiprone
ATE99290T1 (de) Substituierte 4-amino-2-butinyl-harnstoffe und - thioharnstoffe sowie deren derivate als zentral wirkende muscarinische mittel.
ATE313334T1 (de) Behandlung von tumoren mit photodynamischer therapie
RU2002129298A (ru) Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера
DE60327634D1 (de) Mittel zur behandlung des integrationsdysfunktionssyndroms
WO2008057599A3 (en) Methods for the treatment of abeta related disorders and compositions therefor
BR0209985A (pt) Composto e método para o tratamento de um paciente